Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 9, 2020

View Archived Issues

Microglia protect brain via inhibition

NOX5 is a therapeutic target in diabetic kidney disease

Caladrius initiates proof-of-concept study of CLBS-119 for repair of COVID-19-induced lung damage

Hisamitsu Pharmaceutical initiates phase III study of HP-5070 in Japan

Fluvoxamine reduced the likelihood of hospitalization in patients with mild COVID-19

Topline data presented from phase III GALACTIC-HF study of omecamtiv mecarbil

TLC receives approval in Australia and Taiwan for phase I study of TLC-19

CNS leukemia cells depend on fat enzyme to survive and grow

Final data for depatuxizumab mafodotin plus temozolomide in recurrent glioblastoma

Takeda Pharmaceutical patents RIP-2 kinase inhibitors

Yumanity Therapeutics presents new SCD inhibitors

EMPOWER-Lung 1 data for cemiplimab as first-line monotherapy in NSCLC with PD-L1 >= 50%

U.S. researchers identify muscarinic M4 receptor antagonists

Sorrento discovers Salicyn-30 as new inhibitor of SARS-CoV-2 infection in vitro

Saniona AB discloses new KCNN4 blockers

Citius licenses Novellus' iPSC-derived mesenchymal stem cells for acute respiratory conditions

FDA accepts Aprea's IND for APR-548 for TP53 mutant MDS

Spartina developing SIREN technology for COVID-19

BioAtla and BeiGene amend BA-3071 agreement to grant exclusive global license

Selective PDEB inhibitor shows promising preclinical results for the treatment of cocaine addiction

Bavituximab plus pembrolizumab show promising activity in advanced gastric or GEJ cancer

First-in-human data for RO-7122290, a FAP-targeted 4-1BB agonist

Phase IIb study of lenabasum in cystic fibrosis does not meet primary endpoint

FDA clears IND for HLX-70 to treat COVID-19

Phase III study of somatrogon for growth hormone deficiency meets primary endpoint

ILC's Alfacyte shows promise in vitro against SARS-CoV-2

Vincera signs license agreement with Bayer for early development oncology portfolio

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...